BioAtla Inc (NASDAQ: BCAB) on Monday, soared 7.98% from the previous trading day, before settling in for the closing price of $1.63. Within the past 52 weeks, BCAB’s price has moved between $1.14 and $4.02.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -56.91% over the past five years. The company achieved an average annual earnings per share of 34.41%. With a float of $39.01 million, this company’s outstanding shares have now reached $48.08 million.
Let’s look at the performance matrix of the company that is accounted for 65 employees.
BioAtla Inc (BCAB) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of BioAtla Inc is 19.30%, while institutional ownership is 43.38%. The most recent insider transaction that took place on Dec 26 ’23, was worth 9,320. In this transaction Director of this company bought 4,000 shares at a rate of $2.33, taking the stock ownership to the 15,125 shares. Before that another transaction happened on Dec 20 ’23, when Company’s Chief Executive Officer bought 50,000 for $2.14, making the entire transaction worth $106,910. This insider now owns 1,439,283 shares in total.
BioAtla Inc (BCAB) Latest Financial update
#####
According to the Wall Street analysts, stocks earnings will be around 34.41% per share during the next fiscal year.
BioAtla Inc (NASDAQ: BCAB) Trading Performance Indicators
BioAtla Inc (BCAB) is currently performing well based on its current performance indicators. A quick ratio of 3.81 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.50 in one year’s time.
Technical Analysis of BioAtla Inc (BCAB)
BioAtla Inc (NASDAQ: BCAB) saw its 5-day average volume 0.6 million, a negative change from its year-to-date volume of 0.71 million. As of the previous 9 days, the stock’s Stochastic %D was 46.26%. Additionally, its Average True Range was 0.13.
During the past 100 days, BioAtla Inc’s (BCAB) raw stochastic average was set at 27.19%, which indicates a significant decrease from 70.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.38% in the past 14 days, which was lower than the 104.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7111, while its 200-day Moving Average is $2.1813. Nevertheless, the first resistance level for the watch stands at $1.8100 in the near term. At $1.8600, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.9600. If the price goes on to break the first support level at $1.6600, it is likely to go to the next support level at $1.5600. The third support level lies at $1.5100 if the price breaches the second support level.
BioAtla Inc (NASDAQ: BCAB) Key Stats
Market capitalization of the company is 85.08 million based on 48,116K outstanding shares. Right now, sales total 0 K and income totals -123,460 K. The company made 0 K in profit during its latest quarter, and -21,070 K in sales during its previous quarter.
